Loading
A phase 1/2 trial of QLC5508, QL1706, Carboplatin, Cisplatin, QL2107 and Fluorouracil (5-FU) in advanced solid tumours, run by Qilu Pharmaceutical Co., Ltd., now recruiting.
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07256782 by Qilu Pharmaceutical Co., Ltd., with 444 participants planned, started 2025-10-24 and due to reach its primary completion in 2026-10. Interventions recorded: QLC5508, QL1706, Cisplatin/ Carboplatin, QL2107, Paclitaxel and 5-fluorouracil (5-FU).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares QL2107, Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares QLC5508, Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares QLC5508, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/